Key statistics dashboard for Incyte Corporation (INCY). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive a...
Stock Data
| Price | $121.47 |
| Market Cap | $24.6B |
| Enterprise Value | $21.34B |
| Beta | 0.86 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 15.34 |
| Price / Book | 3.94 |
| P/S | 4.35 |
| EV/EBITDA | 10.45 |
| EV/Sales | 3.67 |
| EV/FCF | 11.11 |
| P/FCF | 13.17 |
| Earnings Yield | 6.45% |
| FCF Yield | 7.59% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 92.62% |
| EBIT Margin | 33.85% |
| EBITDA Margin | 35.08% |
| Operating Margin | 31.57% |
| Net Margin | 27.71% |
| Return on Equity | 29.70% |
| Return on Assets | 20.48% |
| Return on Invested Capital | 24.59% |
| Return on Capital Employed | 28.01% |
Financial Health
| Current Ratio | 4.66 |
| Quick Ratio | 4.58 |
| Cash Ratio | 3.04 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.49% |
| Net Debt / EBITDA | -1.93 |
| Interest Coverage | 790.59 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 8.44 |
Per-Share Data
| Revenue per share | 29.04 |
| Book Value per share | 31.66 |
| Cash per share | 22.64 |
| FCF per share | 9.58 |
| Tangible Book Value per share | 30.48 |
| Dividend per share | 0.00 |
Related companies: BIIB · DGX · GMAB · ILMN · RPRX · THC · UTHR
Explore sector: Healthcare · Biotechnology
More sections of INCY: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks